Literature DB >> 17943259

Spontaneous regression of EBV-associated diffuse lymphoproliferative disease in a patient with rheumatoid arthritis after discontinuation of etanercept treatment.

Sung-Hoon Park1, Chae-Gi Kim, Ji-Young Kim, Jung-Yoon Choe.   

Abstract

We describe the case of a 64-year-old female patient with rheumatoid arthritis (RA), who presented with lymphoproliferative disease (LPD) soon after the administration of etanercept, and regressed very shortly after the withdrawal of it. The occurrence was also associated with the Epstein-Barr virus (EBV) infection. The case of our patient may provide the evidence that etanercept plays an etiologic role in LPD in patients with RA.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17943259     DOI： 10.1007/s00296-007-0467-6

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


  14 in total

1.  Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication.

Authors:  Yoshihiko Hoshida; Jing-Xian Xu; Shigeki Fujita; Itsuko Nakamichi; Jun-Ichiro Ikeda; Yasuhiko Tomita; Shin-Ichi Nakatsuka; Jun-Ichi Tamaru; Atsushi Iizuka; Tsutomu Takeuchi; Katsuyuki Aozasa
Journal:  J Rheumatol       Date:  2006-11-15       Impact factor: 4.666

Review 2.  Epidemiology of lymphoma development in patients with rheumatoid arthritis.

Authors:  Anders Ekbom
Journal:  Semin Arthritis Rheum       Date:  2005-04       Impact factor: 5.532

Review 3.  Spontaneous remission of marginal zone B cell lymphoma in a patient with seropositive rheumatoid arthritis after discontinuation of infliximab-methotrexate treatment.

Authors:  R Thonhofer; M Gaugg; M Kriessmayr; H J Neumann; L Erlacher
Journal:  Ann Rheum Dis       Date:  2005-07       Impact factor: 19.103

4.  Rheumatoid arthritis and lymphoma: risky business for B cells.

Authors:  Gordon Starkebaum
Journal:  J Rheumatol       Date:  2007-02       Impact factor: 4.666

Review 5.  A review of Epstein-Barr virus infection in patients with immunodeficiency disorders.

Authors:  M Okano; T G Gross
Journal:  Am J Med Sci       Date:  2000-06       Impact factor: 2.378

6.  Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.

Authors:  Eva Baecklund; Anastasia Iliadou; Johan Askling; Anders Ekbom; Carin Backlin; Fredrik Granath; Anca Irinel Catrina; Richard Rosenquist; Nils Feltelius; Christer Sundström; Lars Klareskog
Journal:  Arthritis Rheum       Date:  2006-03

Review 7.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Authors:  Tim Bongartz; Alex J Sutton; Michael J Sweeting; Iain Buchan; Eric L Matteson; Victor Montori
Journal:  JAMA       Date:  2006-05-17       Impact factor: 56.272

8.  Atypical lymphoproliferation progressing into B-cell lymphoma in rheumatoid arthritis treated with different biological agents: clinical course and molecular characterization.

Authors:  Luca Quartuccio; Valli De Re; Martina Fabris; Alessandra Marzotto; Nicoletta Franzolini; Daniela Gasparotto; Laura Caggiari; Gianfranco Ferraccioli; Cathryn Anne Scott; Salvatore De Vita
Journal:  Haematologica       Date:  2006-05       Impact factor: 9.941

9.  Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.

Authors:  P Geborek; A Bladström; C Turesson; A Gulfe; I F Petersson; T Saxne; H Olsson; L T H Jacobsson
Journal:  Ann Rheum Dis       Date:  2005-02-04       Impact factor: 19.103

10.  The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.

Authors:  Frederick Wolfe; Kaleb Michaud
Journal:  Arthritis Rheum       Date:  2007-05
View more
  7 in total

Review 1.  Tumor necrosis factor blockade and the risk of viral infection.

Authors:  Seo Young Kim; Daniel H Solomon
Journal:  Nat Rev Rheumatol       Date:  2010-02-09       Impact factor: 20.543

2.  Risk of malignancy in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under immunosuppressive therapy: a single-center experience.

Authors:  Marta Fantò; Mario Stefano Peragallo; Mario Pietrosanti; Roberta Di Rosa; Andrea Picchianti Diamanti; Simonetta Salemi; Raffaele D'Amelio
Journal:  Intern Emerg Med       Date:  2015-06-23       Impact factor: 3.397

3.  Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry.

Authors:  X Mariette; F Tubach; H Bagheri; M Bardet; J M Berthelot; P Gaudin; D Heresbach; A Martin; T Schaeverbeke; D Salmon; M Lemann; O Hermine; M Raphael; P Ravaud
Journal:  Ann Rheum Dis       Date:  2009-10-14       Impact factor: 19.103

4.  Anti-TNFα therapy for inflammatory bowel diseases is associated with Epstein-Barr virus lytic activation.

Authors:  Sameer Lapsia; Siva Koganti; Salvatore Spadaro; Ramona Rajapakse; Anupama Chawla; Sumita Bhaduri-McIntosh
Journal:  J Med Virol       Date:  2015-08-31       Impact factor: 2.327

5.  Spontaneous regression of multiple pulmonary nodules in a patient with unclassified renal cell carcinoma following laparoscopic partial nephrectomy: A case report.

Authors:  Kosuke Ueda; Shigetaka Suekane; Tomotaro Mitani; Katsuaki Chikui; Kazuhisa Ejima; Shunsuke Suyama; Makoto Nakiri; Kiyoaki Nishihara; Mitsunori Matsuo; Tsukasa Igawa
Journal:  Mol Clin Oncol       Date:  2016-05-11

6.  Effect of methotrexate and anti-TNF on Epstein-Barr virus T-cell response and viral load in patients with rheumatoid arthritis or spondylarthropathies.

Authors:  Corinne Miceli-Richard; Nicolas Gestermann; Corinne Amiel; Jérémie Sellam; Marc Ittah; Stephan Pavy; Alejandra Urrutia; Isabelle Girauld; Guislaine Carcelain; Alain Venet; Xavier Mariette
Journal:  Arthritis Res Ther       Date:  2009-05-26       Impact factor: 5.156

7.  Clinical use of anti-TNF therapy and increased risk of infections.

Authors:  Tauseef Ali; Sindhu Kaitha; Sultan Mahmood; Abdul Ftesi; Jordan Stone; Michael S Bronze
Journal:  Drug Healthc Patient Saf       Date:  2013-03-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.